Song, Zhengbo
Li, Yuping
Chen, Shiqing
Ying, Shenpeng
Xu, Shuguang
Huang, Jianjin
Wu, Dan
Lv, Dongqing
Bei, Ting
Liu, Shuxun
Huang, Xiaoping
Xie, Congying
Wu, Xiaoyu
Fu, Jianfei
Hua, Feng
Wang, Wenxian
Xu, Chunwei
Gao, Chan
Cai, Shangli
Lu, Shun
Zhang, Yiping http://orcid.org/0000-0001-7039-4226
Funding for this research was provided by:
Foundation of CSCO-Hengrui (Y-HR2019-0173)
Article History
Received: 12 October 2021
Accepted: 10 January 2022
First Online: 1 February 2022
Declarations
:
: The study protocol was approved by each site’s institutional review board in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Written informed consent was provided by each patient before the onset of any trial-related treatment.
: Not applicable.
: Yiping Zhang has read the journal’s policy, and the authors of this manuscript have the following competing interests: SC1 and TB are employees of 3D Medicines Inc. CG and SC2 contributed to this study when they were employees of 3D Medicines Inc. The remaining authors declare no conflict of interest.